Navigation Links
Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
Date:2/13/2008

FRAZER, Pa., Feb. 13 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq: CEPH) issued the following statement in response to a complaint filed today by the U.S. Federal Trade Commission (FTC) in U.S. District Court for the District of Columbia challenging the validity of certain agreements entered into by the company in late 2005 and early 2006 to settle the PROVIGIL(R) (modafinil) [C-IV] patent infringement litigation and seeking to permanently enjoin the Company from maintaining or enforcing these agreements.

Cephalon stands by the strength and validity of our PROVIGIL patents and the legal basis for these settlements. We are disappointed that the FTC has determined to challenge these agreements as we believe they fully comply with both the spirit and letter of the antitrust laws. As importantly, our settlements confer a meaningful benefit to U.S. consumers by providing for the entry of generic modafinil three years early.

Cephalon is prepared to vigorously defend itself in this matter and expects to prevail.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL, FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide) injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone fo
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
2. Cephalon General Counsel John E. Osborn to Resign Position
3. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
4. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
5. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Announces Strong Third Quarter Financial Results
9. Cephalon Quarterly Conference Call Invitation
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
11. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – ... a professor in the Regulatory Biology Laboratory at the Salk ... points to an “off switch” for drug resistance in cancer. ... local research is making a global impact in the fight ... join host Cheryl K. Goodman, CEO of Social Global Mobile ...
(Date:11/18/2014)... American Process Inc. (Atlanta, GA) ... partnership with researchers at Georgia Institute of Technology, ... the USDA’s Forest Products Laboratory to develop ultra-strong, ... is a rapidly emerging high performance nanomaterial extracted ... to replace heavy steel structures within cars, such ...
(Date:11/18/2014)... November 18, 2014 2014 ... Industry is professional and in-depth report on ... basic information, including its definition, characterization, application, ... outline. This exploration covers the worldwide business ... industry examination covering macroeconomic environment & financial ...
(Date:11/18/2014)... Nov. 18, 2014 PDL BioPharma, Inc. (PDL) ... connection with the acquisition of Durata Therapeutics, Inc. by ... with the termination of PDL,s credit agreement with Durata, ... of $40 million, accrued interest, and prepayment and change ... a structured financing transaction with Durata in which PDL ...
Breaking Biology Technology:American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2
... is a little prettier in October as your grocery,s ... Guacamole. Nielsen-ranked, top-selling Wholly Guacamole, is for the second ... from October "PINK" sales to help fight for a ... Texas-Based Wholly,s support for National Breast Cancer Awareness Month. ...
... Oct. 7 Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ) ... to market and other conditions, 27,500,000 shares of its ... of which 16,412,613 shares are being offered through the ... L.P., Lexicon,s largest stockholder. Lexicon also intends to ...
... YORK, Oct. 7 /PRNewswire-FirstCall/ - Healthnostics, Inc. (OTC ... announced today details regarding the social networking features ... the Facebook(C) model that gives individuals greater power ... interactive layer that allows users to comment and ...
Cached Biology Technology:Grocery Produce Fighting for a Cause - Wholly 'Pink' Guacamole 2Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock 2Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock 3Healthnostics' Medbioworld.com Portal Web Site to Include Social Networking Features 2
(Date:11/10/2014)... shelves in early 2010, and people have used them ... be tossed into a washing machine without ever having ... though, has come with risks for young children. , ... found that from 2012 through 2013, U.S. poison control ... years of age swallowing, inhaling, or otherwise being exposed ...
(Date:11/7/2014)... Nov. 7, 2014  In conjunction with the ... Departments, The Community Foundation of the Verdugos has announced the ... JUSTICE PROJECT," a $250,000 initiative to keep the Verdugo Regional ... its first six months of existence, the Lab has processed ... for local law enforcement. "Because our number one ...
(Date:11/6/2014)... -- A groundbreaking paper from a team of Florida ... of how plants could adapt to and survive environmental ... published in the latest issue of the journal ... (the complex of DNA and proteins) is organized in ... that some genes are turned on and others are ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Maize analysis yields whole new world of genetic science 2
... by emphysema and/or chronic bronchitis. It destroys the ... aspects of breathing, which prevents necessary gas exchange. ... of lung infections. These symptoms are associated with ... air sacs, which usually inflate with air during breathing ...
... Contrary to prevailing wisdom, a new study from plant ... family do indeed chaperone proteins across the membranes of chloroplasts, ... findings are published online in the January issue of the ... most crucial tasks in a living cell is to move ...
... available in Spanish . People with lower ... worse health care in the treatment of diabetes than the ... conclusion emerges from a research conducted at the University of ... to date on health care of this disease in the ...
Cached Biology News:New potential to treat chronic obstructive pulmonary disease 2Green plant transport mystery solved 2Poorer diabetics receive worse care than other in countries with universal health coverage 2Poorer diabetics receive worse care than other in countries with universal health coverage 3
... Cell Lines stably express the regulatory ... line is functionally tested for induction ... expression control vector pGene/V5-His/lacZ and by ... with mifepristone (Figure 1). These cell ...
... System Modules Highly ... directional cloning into advanced ... vectors For ... Cloning Systems, the modules ...
... CHEMICON Re-Blot Western Blot Recycling Kit ... from Western blots that have been ... or other isotopes. It is not ... DAB, 4-chloronapthol, etc.), as it is ...
Applications: Western blotting ...
Biology Products: